Is CAR-T therapy a cure?

In some patients, it leads to long-term remission. However, not all patients achieve a cure.

How long do CAR-T cells stay in the body?

Engineered cells may persist for months or even years, depending on the immune response.

Who qualifies for CAR-T therapy?

Typically, patients with relapsed or refractory hematologic cancers meet eligibility criteria.

Can older patients receive CAR-T?

Yes, but risk assessment is critical. Newer designs aim to improve safety in elderly patients.

Home Blogs CAR-T Cell Therapy Beyond Leukemia: What’s Next in Cancer Treatment?

By Dr. Rajesh Bollam

February 12, 2026

CAR-T Cell Therapy Beyond Leukemia: What’s Next in Cancer Treatment?

Key Takeaways

CAR-T delivers >80% remission rates in relapsed B-cell ALL, transforming leukemia outcomes.
Now approved for lymphoma and multiple myeloma, with 50–90% response rates in advanced disease.
Over 1,000 global clinical trials are expanding CAR-T into solid tumours.
Next-gen innovations include dual-target, off-the-shelf, and safer engineered CAR-T designs.
Cost and infrastructure remain barriers, but scalability is improving.
India is emerging in CAR-T development, expanding advanced cellular therapy access.
CAR-T is shifting from last-line rescue to a core precision oncology strategy.

What is CAR-T Cell Therapy

CAR-T cell therapy is a personalised cancer treatment where a patient’s own immune cells are genetically modified to recognise and attack cancer cells.

But the real story is just beginning.

Today, researchers, oncologists, and immunologists worldwide are asking a critical question:

Can CAR-T cell therapy move beyond leukemia and transform treatment for lymphoma, multiple myeloma, and even solid tumours like lung or breast cancer?

This blog explores the science, the evidence, the emerging data, and what the future holds for CAR-T therapy in the next decade.

Revolutionary Next Step in Cancer with CAR-T Cell Therapy

CAR-T cell therapy has already revolutionised treatment for certain blood cancers, particularly relapsed or refractory leukemia. What was once considered experimental is now an established, guideline-supported therapy in advanced hematologic malignancies.

According to the National Cancer Institute, CAR-T (Chimeric Antigen Receptor T-cell) therapy is a type of adoptive cell transfer that enhances the natural cancer-fighting ability of T lymphocytes.

How CAR-T Therapy Works

The treatment process involves multiple highly specialised steps:

T-cells are collected from the patient through leukapheresis
These cells are genetically engineered in a laboratory to express a CAR receptor
The CAR receptor is designed to recognise a specific protein on cancer cells
Modified cells are multiplied in large numbers
After lymphodepleting chemotherapy, the cells are infused back into the patient
The engineered cells seek and destroy cancer cells

Unlike chemotherapy, which kills rapidly dividing cells broadly, CAR-T therapy is highly targeted and immune-based.

Proven Success in Leukemia: The Foundation

CAR-T therapy first demonstrated dramatic results in B-cell Acute Lymphoblastic Leukemia (ALL).

According to data reported by the U.S. Food and Drug Administration:

Complete remission rates in pediatric and young adult relapsed ALL exceeded 80%
Many patients had exhausted all other treatment options
Durable remissions were observed in a significant percentage

The first CAR-T product was approved in 2017. Since then, additional therapies have received regulatory approval. The American Cancer Society highlights that survival in relapsed ALL historically was under 10–20%, making CAR-T a transformational advancement.

Why Leukemia Was Ideal for CAR-T

Leukemia provided a strong starting point because:

Cancer cells circulate in the blood and the bone marrow (easier immune access)
CD19 is a clear and consistent target
Tumour burden can be rapidly reduced

This success created the platform for expansion.

Expansion Beyond Leukemia: Current Approved Indications

CAR-T in Lymphoma

CAR-T therapy is now widely used in aggressive forms of Non-Hodgkin’s Lymphoma (NHL).

Studies published in the New England Journal of Medicine show:

Overall response rates of 50–80% in diffuse large B-cell lymphoma (DLBCL)
Durable complete remission in many patients
Improved survival compared to historical outcomes

Current Focus Areas in Lymphoma

Researchers are working on:

Using CAR-T earlier (second-line instead of third-line)
Reducing relapse rates
Managing resistance mechanisms
Optimising long-term immune persistence

CAR-T is increasingly moving from “last option” to “strategic earlier intervention.”

Multiple Myeloma: A Major Breakthrough

One of the most exciting developments is BCMA-targeted CAR-T therapy for multiple myeloma.

The American Society of Clinical Oncology reports:

Response rates exceeding 70–90% in heavily pretreated patients
Deep MRD-negative remissions
Prolonged progression-free survival

Why BCMA Is a Strong Target

BCMA (B-cell maturation antigen):

It is highly expressed on malignant plasma cells
Has limited expression in normal tissues
Provides a relatively safe therapeutic window

Clinical data published in major journals demonstrate:

Median progression-free survival exceeding 12 months in advanced cases
Significant symptom improvement
Reduced tumour burden even after multiple prior therapies

Importantly, trials are now testing:

CAR-T as second-line therapy
CAR-T in newly diagnosed high-risk patients

This shift signals a new era in plasma cell malignancy treatment.

Solid Tumours: The Most Ambitious Frontier

Can CAR-T Work in Solid Tumours?

Research is ongoing, and progress is real, but challenges remain significant. The Nature Reviews Clinical Oncology emphasises that solid tumours present unique biological barriers.

Key Challenges in Solid Tumours

Unlike blood cancers, solid tumours have:

Physical barriers preventing immune cell infiltration
Immunosuppressive tumour microenvironments
Heterogeneous antigen expression
Risk of damaging normal tissues

Ongoing Clinical Trials

According to ClinicalTrials.gov (U.S. National Library of Medicine database), hundreds of CAR-T trials are investigating solid cancers, including:

Glioblastoma
Ovarian cancer
Pancreatic cancer
Lung cancer
Hepatocellular carcinoma

Research strategies include:

Targeting HER2, GD2, EGFRvIII
Combining CAR-T with checkpoint inhibitors
Engineering CAR-T cells resistant to tumour suppression

While routine clinical use in solid tumours is not yet standard, the pipeline is robust.

Next-Generation CAR-T Innovations

Dual-Target CAR-T Cells

Cancer can escape single-target therapy by losing the targeted antigen.

Dual-target CAR-T cells:

Recognise two tumour markers
Reduce relapse probability
Improvethe durability of response

This strategy is particularly relevant in aggressive lymphomas and leukemia variants.

Off-the-Shelf (Allogeneic) CAR-T Therapy

Current CAR-T manufacturing takes 2–4 weeks.

During this time:

Patients may require bridging therapy
The disease may progress

Allogeneic CAR-T aims to provide:

Immediate availability
Standardized production
Reduced cost over time

The World Health Organisation stresses the importance of scalable therapies for global cancer burden management.

Safer CAR-T Designs

Side effects remain a concern.

Common Toxicities

Cytokine Release Syndrome (CRS)
Immune effector cell-associated neurotoxicity syndrome (ICANS)

The Centres for Disease Control and Prevention describes CRS as a potentially serious inflammatory response, though modern protocols have improved management significantly.

New innovations include:

Built-in safety switches
Tunable CAR signaling
Reduced cytokine intensity engineering

Improved safety may allow:

Use in older patients
Outpatient administration in future
Broader patient eligibility

CAR-NK and Other Cellular Platforms

Beyond T-cells, scientists are engineering:

Natural Killer (NK) cells
Macrophages
Gamma-delta T cells

Potential advantages include:

Lower risk of graft-versus-host disease
Reduced neurotoxicity
Easier mass production

These platforms could represent the next evolution in cellular immunotherapy.

Cost, Accessibility, and Global Expansion

CAR-T therapy remains expensive.

In the U.S., treatment costs can exceed:

$350,000–$475,000 per infusion (excluding hospitalisation)

The National Comprehensive Cancer Network recommends administration only at accredited centres with intensive monitoring capabilities.

Key Barriers

Complex manufacturing
Limited certified centres
ICU-level monitoring
High upfront cost

Indian and Global Perspective

India is emerging as a significant player in CAR-T innovation. According to the International Agency for Research on Cancer:

India reports over 1.4 million new cancer cases annually
Hematologic malignancies remain a substantial burden

India has begun:

Developing indigenous CAR-T platforms
Reducing manufacturing costs
Expanding tertiary oncology centres

Patients searching:

“CAR-T therapy cost in India”
“Is CAR-T available near me?”
“Best hospital for CAR-T in Hyderabad or Delhi?”

will increasingly find growing availability in specialised centres.

What the Future Holds: 5–10 Year Outlook

Experts anticipate:

Earlier integration into treatment algorithms
Combination with immunotherapy drugs
Outpatient CAR-T models
Expanded solid tumour success
Reduced costs through automation

CAR-T is transitioning from:

Experimental therapy To Core oncology strategy

The Future of CAR-T Is Already Taking Shape

CAR-T therapy is advancing quickly. Dual-target designs, off-the-shelf models, and safer engineering are making treatment more effective and accessible. It is also moving earlier in cancer care.

In India, leading oncology centres are building the infrastructure needed for safe cellular therapy delivery.

At Renova Hospitals, multidisciplinary teams and precision-driven protocols support advanced cancer treatments. As research grows, CAR-T is evolving beyond leukemia and becoming a key pillar of personalised cancer care.

Want to connect with a specialist?

Book your appointment now

Book Consultation

Our Panel of Doctors

Our healthcare specialists are equipped with the knowledge and skills to provide you with the support you require. From consultation to diagnosis to treatments, our experts are dedicated to helping you.